drugset / Trial / NCT00162019

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

NCT00162019 ↗

Phase 3 Completed 56 enrolled Baxalta now part of Shire
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to evaluate whether IMMUNATE S/D is effective and safe in the treatment of hemophilia A patients. The study consists of 3 parts: Part 1 is a pharmacokinetic comparison of IMMUNATE S/D and its predecessor IMMUNATE. Part 2 is an evaluation of efficacy and safety of IMMUNATE S/D. Part 3 is a pharmacokinetic study of IMMUNATE S/D.

Timeline

Start
2003-03-31
Primary completion
2004-08-24
Completion
2004-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject IMMUNATE SD Protein / enzyme biologic — —

Indications